Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management
American Journal of Hematology · 2024-12 · 99 (12) · 2367-2378
DOI: 10.1002/ajh.27470 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 06.09.2024. Verfasst von Stephen M Ansell. Beteiligte Einrichtung: Dorotha W. and Grant L. Sundquist Professor in Hematologic Malignancies Research Chair, Division of Hematology, Mayo Clinic, Rochester, Minnesota, US…. Hauptthemen laut MEDLINE: Hodgkin Disease. Die Arbeit wurde bisher 101-mal zitiert (Crossref) und nennt 131 Literaturangaben.
Abstract (Originalsprache)
Disease Overview Hodgkin lymphoma (HL) is an uncommon B‐cell lymphoid malignancy affecting 8570 new patients annually and representing ~10% of all lymphomas in the United States. Diagnosis HL is composed of two distinct disease entities: classical HL and nodular lymphocyte predominant HL (also called nodular lymphocyte predominant B‐cell lymphoma). Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte‐rich HL are subgroups of classical HL. Risk Stratification An accurate assessment of the stage of disease in patients with HL is critical for the selection of the appropriate therapy. Prognostic models that identify patients at low or high risk for recurrence, as well as the response to therapy as determined by positron emission tomography (PET) scan, are used to optimize therapy. Risk‐Adapted Therapy Initial therapy for HL patients is based on the histology of the disease, the anatomical stage and the presence of poor prognostic features. Patients with early‐stage disease are typically treated with combined modality strategies utilizing abbreviated courses of combination chemotherapy followed by involved‐field radiation therapy, whereas those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. However, newer agents including brentuximab vedotin and anti‐PD‐1 antibodies are now standardly incorporated into frontline therapy. Management of Relapsed/Refractory Disease High‐dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. For patients who fail HDCT with ASCT, brentuximab vedotin, PD‐1 blockade, non‐myeloablative allogeneic transplant or participation in a clinical trial should be considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Dorotha W. and Grant L. Sundquist Professor in Hematologic Malignancies Research Chair, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Stephen M Ansell
Zitieren
APA
Ansell, S. M. (2024). Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management. American Journal of Hematology, 99(12), 2367-2378. https://doi.org/10.1002/ajh.27470
Vancouver
Ansell SM. Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management. American Journal of Hematology. 2024;99(12):2367-2378. doi:10.1002/ajh.27470
BibTeX
@article{Ansell2024,
author = {Ansell, Stephen M},
title = {Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management},
journal = {American Journal of Hematology},
year = {2024},
volume = {99},
number = {12},
pages = {2367--2378},
doi = {10.1002/ajh.27470}
}
EUVIMED